内循环!恒瑞与翰森做了大BD

医药财经
Dec 28, 2025

一家将Ⅲ期临床的创新药许可给对方,另一家则为对方的新药提供商业化服务,两家在海外交易中频频出手的医药巨头,转身把合作的手握在了一起。12月28日,恒瑞医药的一则公告披露了两项关联交易:公司将处于Ⅲ期临床试验的SHR6508项目在中国大陆地区的独家开发、生产和商业化权利有偿许可给翰森制药。根据协议,翰森制药须支付首付款3000万元,恒瑞医药还有资格获得最高1.9亿元的里程碑付款及销售提成。同时,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10